Response criteria for intratumoral immunotherapy in solid tumors: ItRECIST
Goldmacher, Gregory V., Khilnani, Anuradha D., Andtbacka, Robert H. I., Luke, Jason J., Hodi, F. Stephen, Marabelle, Aurelien, Harrington, Kevin Joseph, Perrone, Andrea Marie, Tse, Archie N., Madoff, David C., Schwartz, Lawrence Howard
Published in Journal of clinical oncology (20.05.2020)
Published in Journal of clinical oncology (20.05.2020)
Get full text
Journal Article
Correlation of survival outcomes with progression heterogeneity in patients (pts) treated with pembrolizumab (pembro)
Schwartz, Lawrence H., Robey, Seth, Turner, David C., Zhang, Yiwei, Kim, Eunhee, de Alwis, Dinesh, Mogg, Robin, Perrone, Andrea Marie, Oxnard, Geoffrey R.
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article
KEYNOTE-040: A phase III randomized trial of pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer
Cohen, Ezra E. W., Machiels, Jean-Pascal H., Harrington, Kevin J., Burtness, Barbara, Shin, Sang Won, Gause, Christine K., Swift, Ann M., Brown, Holly, Perrone, Andrea Marie, Cheng, Jonathan D., Swaby, Ramona F., Le Tourneau, Christophe
Published in Journal of clinical oncology (20.05.2015)
Published in Journal of clinical oncology (20.05.2015)
Get full text
Journal Article
Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001
Wolchok, Jedd D., Hamid, Omid, Ribas, Antoni, Robert, Caroline, Kefford, Richard, Hwu, Wen-Jen, Weber, Jeffrey S., Joshua, Anthony M, Gangadhar, Tara C., Dronca, Roxana Stefania, Daud, Adil, Patnaik, Amita, Joseph, Richard Wayne, Zarour, Hassane M., Li, Xiaoyun Nicole, Xue, Dahai, Ebbinghaus, Scot, Kang, Soonmo Peter, Perrone, Andrea Marie, Hodi, F. Stephen
Published in Journal of clinical oncology (20.05.2015)
Published in Journal of clinical oncology (20.05.2015)
Get full text
Journal Article
Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475
Hodi, F. Stephen, Ribas, Antoni, Daud, Adil, Hamid, Omid, Robert, Caroline, Kefford, Richard, Hwu, Wen-Jen, Gangadhar, Tara C., Joshua, Anthony M., Hersey, Peter, Weber, Jeffrey S., Dronca, Roxana Stefania, Perrone, Andrea Marie, Gammage, Linda, Hille, Darcy, Xue, Dahai, Kang, Soonmo Peter, Chun, Patrick, Ebbinghaus, Scot, Wolchok, Jedd D.
Published in Journal of clinical oncology (20.05.2014)
Published in Journal of clinical oncology (20.05.2014)
Get full text
Journal Article
Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475
Joseph, Richard Wayne, Elassaiss-Schaap, Jeroen, Wolchok, Jedd D., Joshua, Anthony M., Ribas, Antoni, Hodi, F. Stephen, Hamid, Omid, Robert, Caroline, Daud, Adil, Hwu, Wen-Jen, Kefford, Richard, Hersey, Peter, Weber, Jeffrey S., Patnaik, Amita, De Alwis, Dinesh Prasad, Perrone, Andrea Marie, Kang, Soonmo Peter, Ebbinghaus, Scot, Anderson, Keaven M., Gangadhar, Tara C.
Published in Journal of clinical oncology (20.05.2014)
Published in Journal of clinical oncology (20.05.2014)
Get full text
Journal Article